Company intelligence / Profile preview

Marksans Pharma

Mumbai, Maharashtra, Indiamarksanspharma.com ↗

Ownership: Private
Employees: ~871
Development stage: Other

Overview

Marksans Pharma has over 300 generic products across 10+ therapeutic areas with a strong focus on OTC and prescription solid oral dosage forms. The company has more than 50 FDA-approved products in the US market and over 100 in the UK under its Bells Healthcare brand. It continues to expand its pipeline with new product launches in regulated markets such as the US and UK. Recent approvals include fluoxetine capsules for depression/mood disorders and levonorgestrel tablets for emergency contraception.

Therapeutic areas: NeurologyInfectious DiseasesDermatologyGastroenterologyEndocrinologyOncologyImmunologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Not specifically disclosed but includes major supermarket chains/pharmacy retailers for private label manufacturing in key markets like US & UK

Beyond the preview

Go deeper on Marksans Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marksans Pharma.